Assessing the patient reported outcomes (PROs) of enfortumab vedotin plus pembrolizumab versus platinum-based chemotherapy in patients with advanced urothelial carcinoma in the EV-302 study. Editorial Article

Overview

authors

Okobi, Tobechukwu J

Vaishampayan, Neil

Subramanya, Deepthi

Tagawa, Scott T.

publication date

January 19, 2026

published in

Translational andrology and urology Journal

Identity

PubMed Central ID

PMC12877645

Scopus Document Identifier

105028611370

Digital Object Identifier (DOI)

10.21037/tau-2025-719

PubMed ID

41658443

Additional Document Info

volume

15

issue

1